Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial.

Date publication

août 2024

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe , Dr THIERY-VUILLEMIN Antoine , Dr VERNEREY Dewi , Mr FALCOZ Antoine

Tous les auteurs :
Oudard S, Tran Y, Helissey C, Vauchier C, Ratta R, Bennamoun M, Voog E, Hasbini A, Thiery-Vuillemin A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Vernerey D, Falcoz A, Youcef-Ali K, Kotti S, Lepicard EM, Barthelemy P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39143002

Résumé

The CABASTY study showed that more frequent administration of a lower dose of cabazitaxel (CBZ) reduced toxicity in older men with metastatic castration-resistant prostate cancer (mCRPC), without compromising efficacy. Here, we investigated the impact of a biweekly CBZ schedule on patient-reported pain and health-related quality of life (HRQoL).

Mots clés

Adapted schedule, Cabazitaxel, Functional Assessment of Cancer Therapy—Prostate scores, Pain, Prostate cancer, Quality of life

Référence

Eur Urol Oncol. 2024 08 13;: